Neurocrine (NBIX) has a consensus price target implying 38.8% upside, and the article points to an upward trend in earnings estimate revisions as a potential near-term catalyst. While it notes that price targets are often unreliable, the revision trend is the more supportive signal for the stock.
Neurocrine (NBIX) has a consensus price target implying 38.8% upside, and the article points to an upward trend in earnings estimate revisions as a potential near-term catalyst. While it notes that price targets are often unreliable, the revision trend is the more supportive signal for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
